Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sumitomo/Poxel Wraps Up Japan Pivotal Program for Imeglimin with Successful Long-Term Study
Sumitomo Dainippon Pharma and French partner Poxel said on December 20 that their diabetes treatment imeglimin met the primary endpoint in the last of three studies comprising their pivotal registration program in Japan, putting them on track for their plan…
To read the full story
Related Article
- Sumitomo Dainippon Files Japan NDA for Poxel’s Diabetes Med
July 31, 2020
- Poxel/Sumitomo’s Imeglimin Delivers Again, This Time in Insulin Combo Study
June 26, 2019
- Diabetes Drug Imeglimin Hits Primary Goal in Japan PIII: Sumitomo, Poxel
April 10, 2019
- Sumitomo Dainippon Begins Japan PIII for Poxel’s Diabetes Med
December 28, 2017
- Sumitomo Dainippon In-Licenses Diabetes Med from France’s Poxel
November 1, 2017
BUSINESS
- Efient AGs Launched Just Ahead of 3-Month Supply Deadline
March 4, 2026
- Takeda Targets Psoriasis Market with Zasocitinib, Touts Edge in TYK2 Selectivity
March 4, 2026
- Sumitomo Regains Growth Momentum, Eyes 350 Billion Yen from 2 Key Drugs in FY2028
March 3, 2026
- Middle East Turmoil Raises Fears over API Shipments as Key Airports Shut
March 3, 2026
- UCB, Daiichi Sankyo to Wind Up Japan Partnership for Vimpat
March 3, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…